Jefferies Financial Group Reaffirms “Hold” Rating for Prestige Consumer Healthcare (NYSE:PBH)

Jefferies Financial Group reiterated their hold rating on shares of Prestige Consumer Healthcare (NYSE:PBH) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $76.00 price target on the stock, up from their prior price target of $70.00.

Separately, DA Davidson upped their target price on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a buy rating in a research report on Wednesday, August 28th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of Moderate Buy and a consensus price target of $94.20.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $71.35 on Tuesday. The company has a current ratio of 3.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.65. Prestige Consumer Healthcare has a 1 year low of $56.34 and a 1 year high of $75.80. The company has a market cap of $3.54 billion, a PE ratio of 17.11, a PEG ratio of 2.04 and a beta of 0.48. The company’s 50-day moving average is $71.22 and its two-hundred day moving average is $69.64.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, August 8th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.04. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The company had revenue of $267.10 million for the quarter, compared to the consensus estimate of $260.54 million. During the same period in the prior year, the company posted $1.06 EPS. The company’s revenue was down 4.4% compared to the same quarter last year. Equities analysts anticipate that Prestige Consumer Healthcare will post 4.42 earnings per share for the current year.

Institutional Trading of Prestige Consumer Healthcare

A number of hedge funds have recently modified their holdings of PBH. Congress Asset Management Co. MA raised its position in shares of Prestige Consumer Healthcare by 596.2% in the 4th quarter. Congress Asset Management Co. MA now owns 679,256 shares of the company’s stock valued at $41,584,000 after acquiring an additional 581,685 shares during the period. Norges Bank acquired a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at approximately $27,739,000. Ariel Investments LLC raised its holdings in Prestige Consumer Healthcare by 10.7% during the 2nd quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock worth $195,204,000 after buying an additional 274,212 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in Prestige Consumer Healthcare by 26.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company’s stock worth $90,891,000 after buying an additional 272,773 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in Prestige Consumer Healthcare by 9.0% in the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock valued at $142,827,000 after buying an additional 171,357 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.